ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Head-to-head in vitro susceptibility comparison of temocillin with amoxicillin/clavulanate, piperacillin/tazobactam and meropenem among Enterobacterales isolates in a UK district general hospital.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTemocillin is increasingly used as a carbapenem-sparing agent for infections caused by resistant Enterobacterales; however, comparative data with commonly used β-lactams remain limited. We evaluated the in vitro activity of temocillin compared with amoxicillin/clavulanate, piperacillin-tazobactam and meropenem using a head-to-head approach.
methodsA retrospective laboratory study was conducted on Enterobacterales isolates from urine, blood and respiratory specimens between January and September 2025. Susceptibility testing was performed using EUCAST disc diffusion. Temocillin susceptibility was compared directly with amoxicillin/clavulanate, piperacillin-tazobactam and meropenem for each isolate. Analyses were stratified by ESBL, AmpC and carbapenemase-producing Enterobacterales (CPE) status.
resultsA total of 1,804 isolates were included, of which 861 (47.7%) had resistance mechanism data available. Temocillin demonstrated high overall in vitro activity, with 96.4% of isolates categorised as susceptible (95% CI 95.4-97.2%). Susceptibility to amoxicillin/clavulanate, piperacillin-tazobactam and meropenem was 54.3% (95% CI 52.0-56.6%), 90.9% (95% CI 89.5-92.2%) and 99.9% (95% CI 99.6-100.0%), respectively. Compared with amoxicillin/clavulanate, 53.2% of isolates were susceptible to both agents, while 43.3% were susceptible to temocillin but not amoxicillin/clavulanate, and 2.5% were resistant to both. Against piperacillin-tazobactam, 88.7% of isolates were susceptible to both agents, with 7.7% susceptible to temocillin only and 1.4% resistant to both. Meropenem showed the highest activity; 3.6% of isolates were susceptible to meropenem but not temocillin, while 0.1% were resistant to both. High temocillin activity (> 94%) was observed in ESBL- and AmpC-positive isolates.
conclusionsTemocillin demonstrated high in vitro activity and outperformed amoxicillin/clavulanate while showing comparable activity to piperacillin-tazobactam. Its retained activity in multidrug resistant isolates supports its potential role as a carbapenem-sparing option in antimicrobial stewardship.
Indexed as
Identifiers
42563014What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.